The prognostic significance of tumor-immune microenvironment in ascites of patients with high-grade serous carcinoma

被引:3
|
作者
Miceska, Simona [1 ,2 ]
Skof, Erik [2 ,3 ]
Bucek, Simon [1 ,2 ]
Kuhar, Cvetka Grasic [2 ,3 ]
Gasljevic, Gorana [4 ]
Smrkolj, Spela [2 ,5 ]
Prevodnik, Veronika Kloboves [1 ,6 ,7 ]
机构
[1] Inst Oncol Ljubljana, Dept Cytopathol, Ljubljana, Slovenia
[2] Univ Ljubljana, Fac Med, Ljubljana, Slovenia
[3] Inst Oncol Ljubljana, Dept Med Oncol, Ljubljana, Slovenia
[4] Inst Oncol Ljubljana, Dept Pathol, Ljubljana, Slovenia
[5] Univ Med Ctr, Div Gynaecol & Obstet, Ljubljana, Slovenia
[6] Univ Maribor, Fac Med, Maribor, Slovenia
[7] Dept Cytopathol, Zaloska Cesta 2, SI-1000 Ljubljana, Slovenia
关键词
ascites; immune cells; high-grade serous carcinoma; PD-1; PD-L1; prognostic markers; REGULATORY T-CELLS; INFILTRATING LYMPHOCYTES; OVARIAN-CANCER; FAVORABLE PROGNOSIS; NK-CELL; CD103; PD-1; EXPRESSION; CONTRIBUTE; SURVIVAL;
D O I
10.2478/raon-2023-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. High-grade serous carcinoma (HGSC) is often associated with ascites at presentation. Our objective was to quantify immune cells (ICs) in ascites prior to any treatment was given and evaluate their impact on progres-sion-free survival (PFS) and overall survival (OS). Patients and methods. Forty-seven patients with primary HGSC and ascites were included. Flow-cytometric analysis was performed to detect percentages of CD3(+) T cells (CD4(+), CD8(+), Tregs, and NKT cells), B cells, NK cells (CD56(bright)CD16- and CD56(dim)CD16(+) subsets), macrophages and dendritic cells (DCs). Furthermore, CD103 expression was analyzed on T cells and their subsets, while PD-1 and PD-L1 expression on all ICs. Cut-off of low and high percent-ages of ICs was determined by the median of variables, and correlation with PFS and OS was calculated. Results. CD3(+) cells were the predominant ICs (median 51%), while the presence of other ICs was much lower (me-dian <= 10%). CD103(+) expression was mostly present on CD8(+), and not CD4(+) cells. PD-1 was mainly expressed on CD3(+) T cells (median 20%), lower expression was observed on other ICs (median <= 10%). PD-L1 expression was not detected. High percentages of CD103(+)CD3(+) T cells, PD-1(+) Tregs, CD56(bright)CD16- NK cells, and DCs correlated with prolonged PFS and OS, while high percentages of CD8(+) cells, macrophages, and PD-1(+)CD56(bright)CD16- NK cells, along with low percentages of CD4(+) cells, correlated with better OS only. DCs were the only independent prognostic marker among all ICs. Conclusions. Our results highlight the potential of ascites tumor-immune microenvironment to provide additional prognostic information for HGSC patients. However, a larger patient cohort and longer follow-up are needed to confirm our findings
引用
收藏
页码:493 / 506
页数:14
相关论文
共 50 条
  • [21] Characterization of desmoglein 2 expression in ovarian serous tumors and its prognostic significance in high-grade serous carcinoma
    Chen, Ling
    Liu, Xinxin
    Zhang, Jin
    Liu, Yanxia
    Gao, Ang
    Xu, Yanning
    Lin, Yang
    Du, Qiuyue
    Zhu, Zhengmao
    Hu, Yuanjing
    Liu, Yixin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2018, 11 (10): : 4977 - +
  • [22] Racial differences in the tumor immune landscape and survival of high-grade serous ovarian carcinoma
    Peres, Lauren C.
    Colin-Leitzinger, Christelle
    Sinha, Sweta
    Marks, Jeffrey R.
    Conejo-Garcia, Jose R.
    Alberg, Anthony J.
    Bandera, Elisa V.
    Berchuck, Andrew
    Bondy, Melissa L.
    Christensen, Brock C.
    Cote, Michele L.
    Doherty, Jennifer A.
    Moorman, Patricia G.
    Segura, Carlos Moran
    Nguyen, Jonathan V.
    Peters, Edward S.
    Schwartz, Ann G.
    Terry, Paul D.
    Wilson, Christopher M.
    Fridley, Brooke L.
    Schildkraut, Joellen M.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (01)
  • [23] Defining the tumor immune landscape in a mouse model of high-grade serous carcinoma.
    McCool, Kevin W.
    Kuick, Rork
    Zhai, Yali
    Freeman, Zach
    Wu, Rong
    Fearon, Eric
    Cho, Kathleen R.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 113 - 114
  • [24] Prognostic significance of CXCL12 protein levels in high-grade serous ovarian carcinoma
    Buisseret, Laurence
    Delisle, Vincent
    Communal, Laudine
    Pommey, Sandra
    Stagg, John
    CANCER RESEARCH, 2016, 76
  • [25] Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma
    Siamakpour-Reihani, Sharareh
    Owzar, Kouros
    Jiang, Chen
    Turner, Taylor
    Deng, Yiwen
    Bean, Sarah M.
    Horton, Janet K.
    Berchuck, Andrew
    Marks, Jeffrey R.
    Dewhirst, Mark W.
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2015, 139 (01) : 23 - 29
  • [27] Defining the impact of Chromobox 2 on the immune tumor microenvironment of high grade serous ovarian carcinoma
    Brubaker, Lindsay
    Yamamoto, Tomomi
    Jordan, Kimberly
    Mitra, Siddhartha
    Bitler, Benjamin
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S62 - S63
  • [28] SPATIAL ORGANIZATION OF THE PEDIATRIC HIGH-GRADE GLIOMA TUMOR-IMMUNE LANDSCAPE
    van den Broek, Thijs
    Hoogendijk, Raoull
    Kranendonk, Mariette
    Ruiz, Cristian
    Megchelenbrink, Wout L.
    Lammers, Julie
    Ries, Mario G.
    Hoving, Eelco
    van der Lugt, Jasper
    Rios, Anne C.
    Stunnenberg, Hendrik
    van Vuurden, Dannis
    Zomer, Anoek
    NEURO-ONCOLOGY, 2023, 25
  • [29] The tumor immune microenvironment correlates with neoadjuvant chemotherapy response in high-grade serous ovarian cancer.
    Zhu, Lei
    Cao, Guangming
    Hua, Dingchao
    Cui, Lina
    Zhao, Xiaochen
    Wang, Shuzhen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E17605 - E17605
  • [30] Neoadjuvant Chemotherapy Modulates the Immune Microenvironment in Metastases of Tubo-Ovarian High-Grade Serous Carcinoma
    Bohm, Steffen
    Montfort, Anne
    Pearce, Oliver M. T.
    Topping, Joanne
    Chakravarty, Probir
    Everitt, Gemma L. A.
    Clear, Andrew
    McDermott, Jackie R.
    Ennis, Darren
    Dowe, Thomas
    Fitzpatrick, Amanda
    Brockbank, Elly C.
    Lawrence, Alexandra C.
    Jeyarajah, Arjun
    Faruqi, Asma Z.
    McNeish, Iain A.
    Singh, Naveena
    Lockley, Michelle
    Balkwill, Frances R.
    CLINICAL CANCER RESEARCH, 2016, 22 (12) : 3025 - 3036